<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413828</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH- Breast-AH</org_study_id>
    <nct_id>NCT01413828</nct_id>
  </id_info>
  <brief_title>Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer</brief_title>
  <official_title>Safety and Efficacy Evaluation of Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the published data support the preferential use of an anthracycline-containing&#xD;
      adjuvant regimen for individuals with HER2-positive tumors. Concurrent anthracyclines and&#xD;
      trastuzumab, however, are contraindicated due to the observation of unacceptably high rates&#xD;
      of cardiotoxicity in a large randomized trial in the metastatic setting. However, in&#xD;
      neoadjuvant setting, trastuzumab concurrently with an anthracycline-containing chemotherapy&#xD;
      regimen had shown high pathological complete response (pCR) and very low cardiotoxicity. All&#xD;
      large adjuvant trials have evaluated only the sequential strategy of administering&#xD;
      anthracyclines and trastuzumab. The safety and efficacy of trastuzumab concurrently with an&#xD;
      anthracycline-containing chemotherapy regimen has never been evaluated in adjuvant setting.&#xD;
      Given the similar patients characteristics, the investigators hypothesize that trastuzumab&#xD;
      concurrently with an anthracycline-containing chemotherapy regimen would not increase&#xD;
      cardiotoxicity but efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiotoxicity</measure>
    <time_frame>2 years</time_frame>
    <description>the heart failure rate will be compared at 2 years, and left ventricular ejection fraction (LVEF) changes will be monitored during 3, 6, 9, 12, 24 months after firs dose of drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years and 5 years</time_frame>
    <description>local recurrence, regional recurrence, contralateral breast recurrence, distant metastasis, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate (CTCAE v. 3.0)</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events other than cardiotoxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>concurrent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trastuzumab was administered concurrently with any anthracycline-containing adjuvant regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sequential</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>trastuzumab was administered sequentially to any anthracycline-containing adjuvant regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>concurrent</intervention_name>
    <description>Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.</description>
    <arm_group_label>concurrent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sequential</intervention_name>
    <description>Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.</description>
    <arm_group_label>sequential</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Histological diagnosis of operable invasive adenocarcinoma of the breast. Tumours must&#xD;
             be HER2 positive. Time window between surgery and study randomization must be less&#xD;
             than 60 days.&#xD;
&#xD;
          -  Surgery must consist of mastectomy or conservative surgery with axillary lymph node&#xD;
             dissection or sentinel lymph node biopsy. Margins free of disease and ductal&#xD;
             carcinomas in situ (DCIS) are required. Lobular carcinoma is not considered a positive&#xD;
             margin.&#xD;
&#xD;
          -  Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of&#xD;
             disease. If sentinel node technique is used, sentinel node can be the only node&#xD;
             affected.&#xD;
&#xD;
          -  Status of hormone receptors in primary tumour must be available before the end of&#xD;
             adjuvant chemotherapy.&#xD;
&#xD;
          -  Patients must not present evidence of metastatic disease. Status of HER2 in primary&#xD;
             tumour, known before randomization. Patients with immune histochemistry (IHC) 3+ are&#xD;
             eligible. For patients with ICH 2+, fluorescence in situ hybridization (FISH) is&#xD;
             mandatory and result must be positive.&#xD;
&#xD;
          -  Age &gt;= 18 and &lt;= 70 years old.&#xD;
&#xD;
          -  Performance status (Karnofsky index) &gt;= 80.&#xD;
&#xD;
          -  Normal electrocardiogram (EKG) in the 12 weeks prior to randomization.&#xD;
&#xD;
          -  Cardiac function monitored by left ventricular ejection fraction (LVEF) must be &gt;=&#xD;
             55%.&#xD;
&#xD;
          -  Laboratory results (within 14 days prior to randomization):&#xD;
&#xD;
               -  Hematology: neutrophils &gt;= 1.5 x 10^9/l; platelets &gt;= 100 x 10^9/l; hemoglobin &gt;=&#xD;
                  10 mg/dl;&#xD;
&#xD;
               -  Hepatic function: total bilirubin &lt;= 1 upper normal limit (UNL); SGOT and SGPT &lt;=&#xD;
                  2.5 UNL; alkaline phosphatase &lt;= 2.5 UNL. If values of SGOT and SGPT &gt; 1.5 UNL&#xD;
                  are associated to alkaline phosphatase &gt; 2.5 UNL, patient is not eligible;&#xD;
&#xD;
               -  Renal function: creatinine &lt;= 175 mmol/l (2 mg/dl); creatinine clearance &gt;= 60&#xD;
                  ml/min;&#xD;
&#xD;
          -  Complete stage workup during the 12 weeks prior to randomization (mammograms are&#xD;
             allowed within a 20 week window). All patients must have a bilateral mammogram, thorax&#xD;
             x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or&#xD;
             alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is&#xD;
             recommended for all patients. Other tests: as clinically indicated.&#xD;
&#xD;
          -  Patients able to comply with treatment and study follow-up.&#xD;
&#xD;
          -  Negative pregnancy test done in the 14 prior days to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy for breast cancer.&#xD;
&#xD;
          -  Prior therapy with anthracyclines or trastuzumab for any malignancy.&#xD;
&#xD;
          -  Prior radiotherapy for breast cancer.&#xD;
&#xD;
          -  Bilateral invasive breast cancer.&#xD;
&#xD;
          -  Pregnant or lactating women. Adequate contraceptive methods must be used during&#xD;
             chemotherapy and hormone therapy treatments.&#xD;
&#xD;
          -  Any M1 tumor.&#xD;
&#xD;
          -  HER2 negative breast cancer (IHC 0or 1+ or negative FISH result).&#xD;
&#xD;
          -  Pre-existing grade &gt;= 2 motor or sensorial neurotoxicity (National Cancer Institute&#xD;
             Common Toxicity Criteria version 2.0 [NCI CTC v-2.0]).&#xD;
&#xD;
          -  Any other serious medical pathology, such as congestive heart failure; unstable&#xD;
             angina; history of myocardial infarction during the previous year; uncontrolled HA or&#xD;
             high risk arrhythmias.&#xD;
&#xD;
          -  left ventricular ejection fraction (LVEF) less than 55%.&#xD;
&#xD;
          -  History of neurological or psychiatric disorders, which could preclude the patients&#xD;
             from free informed consent.&#xD;
&#xD;
          -  Active uncontrolled infection.&#xD;
&#xD;
          -  Active peptic ulcer; unstable diabetes mellitus.&#xD;
&#xD;
          -  Previous or current history of neoplasms different from breast cancer, except for skin&#xD;
             carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and&#xD;
             without recurrence in the last 10 years; ductal in situ carcinoma in the same breast;&#xD;
             lobular in situ carcinoma.&#xD;
&#xD;
          -  Chronic treatment with corticosteroids.&#xD;
&#xD;
          -  Contraindications for corticosteroid administration.&#xD;
&#xD;
          -  Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor&#xD;
             modulators (SERMs), either for osteoporosis treatment or for prevention. These&#xD;
             treatments must stop before randomisation.&#xD;
&#xD;
          -  Concomitant treatment with other investigational products; participation in other&#xD;
             clinical trials with a non-marketed drug in the 20 previous days before randomization.&#xD;
&#xD;
          -  Concomitant treatment with another therapy for cancer.&#xD;
&#xD;
          -  Males.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Qiang, Master</last_name>
    <role>Study Chair</role>
    <affiliation>PUMCH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>trastuzumab</keyword>
  <keyword>anthracycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

